Letters to the editor: Nicotinic acetylcholine receptor ligands as potential targets for managing neuropathic pain induced by diabetic peripheral neuropathy

Authors

Sarah Westlake, NYIT Osteopathic at A-State
Matthew Jones, NYIT Osteopathic at A-State
Krishna D. Sharma, Arkansas Biosciences Institute at A-State
Jennifer Yanhua Xie, NYIT Osteopathic at A-State

Document Type

Article

Publication Title

eNeurologicalSci

PubMed ID

35855978

Abstract

Diabetic peripheral neuropathy (DPN) is a medical condition that is progressively becoming more prevalent. The underlying cause of DPN is still unknown, although there have been several hypothesized mechanisms. There are current pharmaceutical treatments used to manage the pain, but their efficacy is largely unsatisfactory and are often associated with serious adverse effects. This review will explore the evidence of a new potential target for treating DPN, the ligands for nicotinic acetylcholine receptors (nAChRs), specifically α4ꞵ2 agonists and α9α10 antagonists.

First Page

100416

DOI

10.1016/j.ensci.2022.100416

Publication Date

9-1-2022

Recommended Citation

Westlake, Sarah; Jones, Matthew; Sharma, Krishna D.; and Xie, Jennifer Yanhua, "Letters to the editor: Nicotinic acetylcholine receptor ligands as potential targets for managing neuropathic pain induced by diabetic peripheral neuropathy" (2022). Arkansas Biosciences Institute. 27.
https://arch.astate.edu/abi/27